| Literature DB >> 28723569 |
Kate E Lawlor1, Rebecca Feltham2, Monica Yabal3, Stephanie A Conos2, Kaiwen W Chen4, Stephanie Ziehe3, Carina Graß3, Yifan Zhan2, Tan A Nguyen2, Cathrine Hall5, Angelina J Vince5, Simon M Chatfield2, Damian B D'Silva5, Kenneth C Pang6, Kate Schroder4, John Silke2, David L Vaux2, Philipp J Jost3, James E Vince7.
Abstract
X-linked Inhibitor of Apoptosis (XIAP) deficiency predisposes people to pathogen-associated hyperinflammation. Upon XIAP loss, Toll-like receptor (TLR) ligation triggers RIPK3-caspase-8-mediated IL-1β activation and death in myeloid cells. How XIAP suppresses these events remains unclear. Here, we show that TLR-MyD88 causes the proteasomal degradation of the related IAP, cIAP1, and its adaptor, TRAF2, by inducing TNF and TNF Receptor 2 (TNFR2) signaling. Genetically, we define that myeloid-specific cIAP1 loss promotes TLR-induced RIPK3-caspase-8 and IL-1β activity in the absence of XIAP. Importantly, deletion of TNFR2 in XIAP-deficient cells limited TLR-MyD88-induced cIAP1-TRAF2 degradation, cell death, and IL-1β activation. In contrast to TLR-MyD88, TLR-TRIF-induced interferon (IFN)β inhibited cIAP1 loss and consequent cell death. These data reveal how, upon XIAP deficiency, a TLR-TNF-TNFR2 axis drives cIAP1-TRAF2 degradation to allow TLR or TNFR1 activation of RIPK3-caspase-8 and IL-1β. This mechanism may explain why XIAP-deficient patients can exhibit symptoms reminiscent of patients with activating inflammasome mutations.Entities:
Keywords: NLRP3; RIPK3; TNFR2; Toll-like receptor; XIAP; autoinflammatory disease; cIAP1; caspase-8; interferon; necroptosis
Mesh:
Substances:
Year: 2017 PMID: 28723569 DOI: 10.1016/j.celrep.2017.06.073
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423